IRAK2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL21105720	1.00	1/20
SCHEMBL21106082	1.00	1/20
SCHEMBL23763239	1.00	1/20
SCHEMBL23860570	1.00	1/20
SCHEMBL30264224	1.00	1/20
SCHEMBL21070419	0.86	1/20
SCHEMBL21107419	0.86	1/20
SCHEMBL31664231	0.86	1/20
SCHEMBL22906395	0.84	1/20
SCHEMBL23945382	0.84	1/20
SCHEMBL23945438	0.84	1/20
SCHEMBL21105861	0.80	1/20
SCHEMBL21105862	0.80	1/20
SCHEMBL23805965	0.80	1/20
SCHEMBL23805969	0.80	1/20
SCHEMBL23806365	0.80	1/20
SCHEMBL21105776	0.78	1/20
SCHEMBL21105777	0.77	1/20
SCHEMBL21069405	0.76	1/20
SCHEMBL21106847	0.76	1/20

Clinical trials — most relevant to IRAK2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis	PHASE4	NOT_YET_RECRUITING
Efficacy and Safety of Ivarmacitinib Monotherapy in the Treatment of csDMARDs-IR Rheumatoid Arthritis	PHASE4	NOT_YET_RECRUITING
Clinical Evaluation of the Effect of Metformin in Sepsis	PHASE3	UNKNOWN
Reducing Abundance of Human Papilloma Virus in Women by Taking Probiotic	PHASE2/PHASE3	WITHDRAWN
Efficacy of Vitamin D on the Clinical Management of Pediatric Patients With Asthma	PHASE3	UNKNOWN
IRAK 4 Inhibitor (PF-06650833) in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation.	PHASE2	UNKNOWN
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms	PHASE1/PHASE2	RECRUITING
Cilostazol in Parkinson's Disease	PHASE2	NOT_YET_RECRUITING
Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis	PHASE2	COMPLETED
HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia	PHASE1	NOT_YET_RECRUITING
The Effects of GLA on Human Volunteers	PHASE1	COMPLETED
Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined	EARLY_PHASE1	RECRUITING
RNA Cloning and Visualization in Human Atherosclerosis	nan	COMPLETED
MicroRNAs and Cytokines in Peri-Implantitis Tissue	nan	UNKNOWN
Deep Phenotyping of Cutaneous Lupus Erythematosus	nan	UNKNOWN
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry Bad Cholesterol in the Blood	nan	COMPLETED
Toll-like Receptor 2 Gene Polymorphism, Serum Cytokines and Susceptibility to Disease Severity or Treatment Response of Pulmonary Tuberculosis	nan	COMPLETED
Probiotics and Systemic Inflammation in Patients With Metabolic Syndrome and High Cardiovascular Risk	nan	WITHDRAWN
Activation of a Cutaneous Inflammasome in the Skin of Hidradenitis Suppurativa Patients	nan	COMPLETED
The Mechanisms and Significances of Synergistic Effects of Mycophenolic Acid and LPS on IL-1β Secretion by Mononuclear	nan	UNKNOWN
The Role of Toll-like Receptor-4 in Periodontitis Patients With End-stage Renal Disease in a Sample of Egyptian Population	nan	RECRUITING
miR-155 Expression in Episodic and Chronic Migraine	nan	UNKNOWN
Effect of Periodontal Treatment on Inflammasome Proteins in Periodontal Diseases	nan	UNKNOWN
Novel Biomarkers in Inflammatory Bowel Disease	nan	COMPLETED
Pathogenesis of BTK-mediated Hyper-Inflammatory Responses in COVID-19 (RESPOND)	nan	WITHDRAWN
Clinical Study on the Application of PET Probes Targeting DDR2 in the Diagnosis of Interstitial Lung Disease With Cognitive Impairment	nan	NOT_YET_RECRUITING
Role of ST2 in Acute Pancreatitis	nan	COMPLETED
Role of IL 12 and IL 23 as Potential Biomarkers in Diagnosis of Early Crohn's Disease	nan	COMPLETED
Genetic Variation in TRAF3IP2 (rs13190932)	nan	RECRUITING
Role of Type 2 Diabetes in Potentiating the Inflammatory Response Post Extracorporeal Circulation After Cardiac Surgery	nan	WITHDRAWN

Related proteins — ESM-2 sequence neighbours (a IRAK2 binder may also engage these)

Protein	Name	Similarity
Q5R810	—	1.000	Q5R810 →
Q0P5I2	—	1.000	Q0P5I2 →
Q8CFA1	—	1.000	Q8CFA1 →
Q4QQS0	—	1.000	Q4QQS0 →
Q2LGB3	—	0.995	Q2LGB3 →
Q62406	—	0.995	Q62406 →
Q8R2S1	—	0.991	Q8R2S1 →
Q68UT7	—	0.990	Q68UT7 →
IRAK1	Interleukin-1 receptor-associated kinase 1	0.990	landscape →
Q5BIW4	—	0.989	Q5BIW4 →
O95238	—	0.989	O95238 →
Q5RAJ5	—	0.989	Q5RAJ5 →
RIPK3	Receptor-interacting serine/threonine-protein kinase 3	0.989	landscape →
Q9Y6S9	—	0.988	Q9Y6S9 →
Q8VDG6	—	0.988	Q8VDG6 →
Q4VSN4	—	0.988	Q4VSN4 →
Q8QHJ9	—	0.988	Q8QHJ9 →
Q68DX3	—	0.988	Q68DX3 →
Q8K330	—	0.988	Q8K330 →
Q9D684	—	0.988	Q9D684 →
O70405	—	0.988	O70405 →
Q8BW88	—	0.987	Q8BW88 →
Q9QZ05	—	0.987	Q9QZ05 →
Q6TXD4	—	0.987	Q6TXD4 →
D4A7V9	—	0.987	D4A7V9 →
Q6XUX1	—	0.987	Q6XUX1 →
Q9QZL0	—	0.987	Q9QZL0 →
MAP3K9	Mitogen-activated protein kinase kinase kinase 9	0.987	landscape →
Q80VA5	—	0.987	Q80VA5 →
Q5RA67	—	0.987	Q5RA67 →